Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Duchenne Muscular Dystrophy (DMD) Treatment Market: By Therapeutic Approaches: Molecular-based Therapies, Steroid Therapy, Others; By Distribution Channel; By End Users; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments

Global Duchenne Muscular Dystrophy (DMD) Treatment Market Outlook

The global market for Duchenne muscular dystrophy (DMD) treatment reached a value of about USD 1.15 million in 2021. The industry is further expected to grow at a CAGR of approximately 12.50% in the forecast period of 2023-2028 to reach a value of around USD 2.34 million by 2027.

 

duchenne muscular dystrophy dmd treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America and Europe to be Significant Regional Markets for Duchenne Muscular Dystrophy (DMD) Treatment

North America and Europe are currently the two largest markets in the global Duchenne muscular dystrophy (DMD) treatment market as these are expected to account for a large proportion of the market in the forecast period. New product innovations, rising incidence of Duchenne muscular dystrophy, rise in the demand for early diagnosis, high healthcare expenditure, increasing investments in research and development of new treatment options, and government awareness programs are the major factors anticipated to propel the market growth in these regions. The United States is the dominant country in North America and is projected to maintain its lead due to rising disease incidence and the anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with increasing clinical trials around the world, especially in the United States and Europe.

 

Exon Skipping Segment Expected to Dominate the Market Growth

The increasing adoption of EXONDYS 51 has driven the segment growth. EXONDYS 51 refers to the first FDA-approved Duchenne muscular dystrophy treatment for patients who suffer from a confirmed genetic mutation in the dystrophin gene, which can be treated by skipping exon 51. It helps the body make a shorter form of the dystrophin protein in some patients. The internal deletions mainly cause Duchenne muscular dystrophy in the gene for dystrophin, a protein essential for maintaining muscle cell membrane integrity. One of the potential therapeutic methods is to mask an exon close to the site where the others are missing so that the remaining exons can join together. Exon-skipping approach signifies one of the most capable therapeutic approaches that aim to restore the expression of a shorter but functional dystrophin protein.

Also, the market players are increasingly focusing on frequent launches in exon-skipping technology, which is a significant factor driving the segment and propelling the growth of the Duchenne muscular dystrophy (DMD) treatment market. For instance, In December 2019, Sarepta’s exon-skipping drug, VYONDYS 53 (golodirsen), was approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy.

 

Market Segmentations

Duchenne muscular dystrophy (DMD) is a hereditary condition that causes muscle weakening and deterioration. DMD is caused by a mutation in the gene that codes for the dystrophin protein, which is found in muscles. It is a rare muscular condition that usually affects men. Intellectual incapacity, muscle weakness, and walking and breathing difficulties are among the common symptoms.

 

duchenne muscular dystrophy dmd treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on therapeutic approaches, the market is segmented into:

  • Molecular-based Therapies
    • Mutation Suppression
    • Exon Skipping
  • Steroid Therapy
  • Other Therapeutic Approaches

The several distribution channels of the market are:

  • Hospitals 
  • Retail and Online Pharmacies

The end-users of the market are:

  • Hospitals
  • Home Care Settings
  • Clinics

The regional markets for the Duchenne muscular dystrophy (DMD) treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

duchenne muscular dystrophy dmd treatment market by region\

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Introduction of Novel Drugs and Therapies Augmenting the Market Growth

The major drivers in the global Duchenne muscular dystrophy (DMD) treatment market include the introduction of novel drugs and therapies, significant support from various firms for drug research, disease-modifying therapies, and support from patient advocacy groups on the regulatory approval process. An increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy and a broad product pipeline are likely to drive the global market growth during the forecast period. Mutation-specific therapies are expected to emerge as a breakthrough in the treatment of Duchenne muscular dystrophy. The increasing disease burden of Duchenne muscular dystrophy, increased investments in biopharmaceutical research and development to release novel disease therapeutics, and increased DMD awareness campaigns also contribute to the market's growth. Various organisations are involved in spreading awareness and investing in research and development to find an effective treatment for this disease, contributing to the global market growth. Other factors, such as constant research on gene therapy, stem cell therapy, and exon skipping drugs for the treatment of DMD, are expected to propel the market growth of DMD treatment. Additionally, favourable reimbursement policies and government initiatives supporting target-specific therapies are anticipated to fuel the market during the forecasted period.

 

Key Players in the Market for Global Duchenne Muscular Dystrophy (DMD) Treatment

The report gives a detailed analysis of the following key players in the global Duchenne muscular dystrophy (DMD) treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • PTC Therapeutics Inc.
  • FibroGen, Inc
  • F. Hoffmann-La Roche Ltd
  • NS Pharma, Inc.
  • Solid Biosciences Inc.
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapeutic Approaches
  • Distribution Channel
  • End Users
  • Region
Breakup by Therapeutic Approaches
  • Molecular-based Therapies
    • Mutation Suppression
    • Exon Skipping
  • Steroid Therapy
  • Other Therapeutic Approaches
Breakup by Distribution Channel
  • Hospitals 
  • Retail and Online Pharmacies
Breakup by End Users
  • Hospitals
  • Home Care Settings
  • Clinics
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • PTC Therapeutics Inc.
  • FibroGen, Inc
  • F. Hoffmann-La Roche Ltd
  • NS Pharma, Inc.
  • Solid Biosciences Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market (2018-2022) 
    8.3    Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast (2023-2028)
    8.4    Global Duchenne Muscular Dystrophy (DMD) Treatment Market by Therapeutic Approaches
        8.4.1    Molecular-based Therapies
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2022)
            8.4.1.3    Forecast Trend (2023-2028)
            8.4.1.4    Breakup by Type
                8.4.1.4.1    Mutation Suppression
                8.4.1.4.2    Exon Skipping
        8.4.2    Steroid Therapy
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2022)
            8.4.2.3    Forecast Trend (2023-2028)
        8.4.3    Other Therapeutic Approaches
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2018-2022)
            8.4.3.3    Forecast Trend (2023-2028)
    8.5    Global Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
        8.5.1    Hospitals 
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2022)
            8.5.1.3    Forecast Trend (2023-2028)
        8.5.2    Retail and Online Pharmacies
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2022)
            8.5.2.3    Forecast Trend (2023-2028)
    8.6    Global Duchenne Muscular Dystrophy (DMD) Treatment Market by End Users
        8.6.1    Hospitals
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2018-2022)
            8.6.1.3    Forecast Trend (2023-2028)
        8.6.2    Home Care Settings
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2018-2022)
            8.6.2.3    Forecast Trend (2023-2028)
        8.6.3    Clinics
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2018-2022)
            8.6.3.3    Forecast Trend (2023-2028)
    8.7    Global Duchenne Muscular Dystrophy (DMD) Treatment Market by Region       
        8.7.1    North America
           8.7.1.1    Market Share
           8.7.1.2    Historical Trend (2018-2022) 
           8.7.1.3    Forecast Trend (2023-2028)
       8.7.2    Europe
           8.7.2.1    Market Share
           8.7.2.2    Historical Trend (2018-2022) 
           8.7.2.3    Forecast Trend (2023-2028)
       8.7.3    Asia Pacific
           8.7.3.1    Market Share
           8.7.3.2    Historical Trend (2018-2022) 
           8.7.3.3    Forecast Trend (2023-2028)
       8.7.4    Latin America
           8.7.4.1    Market Share
           8.7.4.2    Historical Trend (2018-2022) 
           8.7.4.3    Forecast Trend (2023-2028)
       8.7.5    Middle East and Africa
           8.7.5.1    Market Share
           8.7.5.2    Historical Trend (2018-2022) 
           8.7.5.3    Forecast Trend (2023-2028)
9    North America Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2018-2022) 
        9.1.3    Forecast Trend (2023-2028)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2018-2022) 
        9.2.3    Forecast Trend (2023-2028)
10    Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2018-2022) 
        10.1.3    Forecast Trend (2023-2028)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2018-2022) 
        10.2.3    Forecast Trend (2023-2028)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2018-2022) 
        10.3.3    Forecast Trend (2023-2028)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2018-2022) 
        10.4.3    Forecast Trend (2023-2028)
    10.5    Others
11    Asia Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
    11.1    China    
        11.1.1    Market Share
        11.1.2    Historical Trend (2018-2022) 
        11.1.3    Forecast Trend (2023-2028)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2018-2022) 
        11.2.3    Forecast Trend (2023-2028)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2018-2022) 
        11.3.3    Forecast Trend (2023-2028)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2018-2022) 
        11.4.3    Forecast Trend (2023-2028)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2018-2022) 
        11.5.3    Forecast Trend (2023-2028)
    11.6    Others
12    Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2018-2022) 
        12.1.3    Forecast Trend (2023-2028)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2018-2022) 
        12.2.3    Forecast Trend (2023-2028)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2018-2022) 
        12.3.3    Forecast Trend (2023-2028)
    12.4    Others
13    Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2018-2022) 
        13.1.3    Forecast Trend (2023-2028)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2018-2022) 
        13.2.3    Forecast Trend (2023-2028)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2018-2022) 
        13.3.3    Forecast Trend (2023-2028)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2018-2022) 
        13.4.3    Forecast Trend (2023-2028)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Pfizer Inc.
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Sarepta Therapeutics, Inc.
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    PTC Therapeutics Inc.
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    FibroGen, Inc
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    F. Hoffmann-La Roche Ltd
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    NS Pharma, Inc.
            15.2.6.1    Company Overview
            15.2.6.2    Product Portfolio
            15.2.6.3    Demographic Reach and Achievements
            15.2.6.4    Certifications
        15.2.7    Solid Biosciences Inc.
            15.2.7.1    Company Overview
            15.2.7.2    Product Portfolio
            15.2.7.3    Demographic Reach and Achievements
            15.2.7.4    Certifications
        15.2.8    Others
16    Key Trends and Developments in the Market

 

List of Key Figures and Tables

1.    Global Duchenne Muscular Dystrophy (DMD) Treatment Market: Key Industry Highlights, 2018 and 2028
2.    Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Therapeutic Approaches (USD Million), 2018-2022
3.    Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Therapeutic Approaches (USD Million), 2023-2028
4.    Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
5.    Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
6.    Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup End Users (USD Million), 2018-2022
7.    Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by End Users (USD Million), 2023-2028
8.    Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Region (USD Million), 2018-2022
9.    Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Region (USD Million), 2023-2028
10.    North America Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
11.    North America Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
12.    Europe Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
13.    Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
14.    Asia Pacific Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
15.    Asia Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
16.    Latin America Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
17.    Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
18.    Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
19.    Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
20.    Global Duchenne Muscular Dystrophy (DMD) Treatment Market Structure

Key Questions Answered in the Report

In 2021, the global market attained a value of nearly USD 1.15 million.

The market is projected to grow at a CAGR of 12.50% between 2023 and 2028.

The market is estimated to witness healthy growth in the forecast period of 2023-2028 to reach USD 2.34 million by 2027.

The major drivers of the market include the rising disease incidence, anticipated launch of promising pipeline candidates, significant support from various firms for drug research, increased investments in biopharmaceutical research and development to release novel disease therapeutics, increased DMD awareness campaigns, favourable reimbursement policies and government initiatives supporting target-specific treatments.

The introduction of novel drugs and therapies and an increase in the number of clinical trials are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on therapeutic approaches, the market is segmented into molecular-based therapies and steroid therapy, among other therapeutic approaches. Molecular-based therapies are further divided into mutation suppression and exon skipping.

The several distribution channels of the market are hospitals, retail, and online pharmacies.

The end-users of the market are hospitals, home care settings, and clinics.

The major players in the industry include Pfizer Inc., Sarepta Therapeutics, Inc., PTC Therapeutics Inc., FibroGen, Inc, F. Hoffmann-La Roche Ltd, NS Pharma, Inc., and Solid Biosciences Inc., among others.

Analyst Review

The global Duchenne muscular dystrophy (DMD) treatment market attained a value of USD 1.15 million in 2021, driven by the introduction of novel drugs and therapies. Aided by the increased DMD awareness campaigns and an increase in the number of clinical trials, the market is expected to witness further growth in the forecast period of 2023-2028, growing at a CAGR of 12.50%. The market is projected to reach USD 2.34 million by 2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on therapeutic approaches, the market is segmented into molecular-based therapies and steroid therapy, among other therapeutic approaches. Molecular-based treatments are further divided into mutation suppression and exon skipping. The several distribution channels of the market are hospitals, retail and online pharmacies. The end-users of the market are hospitals, home care settings, and clinics. The major regional markets for Duchenne muscular dystrophy (DMD) treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the Duchenne muscular dystrophy (DMD) treatment market include Pfizer Inc., Sarepta Therapeutics, Inc., PTC Therapeutics Inc., FibroGen, Inc, F. Hoffmann-La Roche Ltd, NS Pharma, Inc., and Solid Biosciences Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER